Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds

This study has been completed.
Information provided by (Responsible Party):
Healthpoint Identifier:
First received: August 26, 2010
Last updated: December 1, 2011
Last verified: December 2010
The goal for this study is to examine the persistence of growth arrested,allogeneic,male-donor keratinocytes and fibroblasts when applied as product HP802-247 to the surface of acute excisional wounds in health female volunteers, as measured using Y-STR for detection of Y-chromosome.

Condition Intervention Phase
Normal Female Volunteers
Biological: HP802-247
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study Investigating the Survival of HP802-247 Allogeneic Cells in Excisional Acute Cutaneous Wounds

Further study details as provided by Healthpoint:

Primary Outcome Measures:
  • Presence of Y Chromosome Genetic Markers [ Time Frame: 57 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Identification of Donor Cell Type [ Time Frame: 57 Days ] [ Designated as safety issue: No ]

Enrollment: 28
Study Start Date: September 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
Biological: HP802-247
One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provide written informed consent.
  • Female, 18 years of age or older.
  • Any race or skin type, provided that there are no tattoos within 5 cm of the wound target, and the gentian violet surgical marker produces a clearly visible mark on the skin.
  • Willing to make all required study visits and, in the opinion of the Investigator, able to follow instructions.
  • Willing to undergo the repeated biopsy procedures.
  • Willing to undergo verification of sex chromosome status.

Exclusion Criteria:

  • Males, or phenotypic females bearing Y-chromosome genetic material [e.g., 46,X,(r)Y; 46,X,der(X)t(X;Y); sex reassignment surgery].
  • Contraindications or hypersensitivity to the use of the study medications or their components (e.g., history of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, or amphotericin B).
  • History of keloid formation or hypertrophic scarring.
  • Participation in any interventional clinical trial within 30 days prior to screening.
  • History of prolonged bleeding, bleeding into joints, easy bruising following minor trauma, clotting factor deficiency, or current use of anticoagulants or platelet inhibitors.
  • Any medical condition which, in the opinion of the Co-Investigator, may interfere with normal wound repair.
  • Current therapy with drugs or biologics intended to function as immuno-suppressants, chronic (> 10 days) oral corticosteroids, or any concomitant medication which, in the opinion of the Co-Investigator, may interfere with normal wound repair.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01190865

United States, Texas
RCTS, Inc.
Irving, Texas, United States
Sponsors and Collaborators
Study Chair: Herbert B Slade, MD Healthpoint, Ltd
Principal Investigator: Barry Reece, MS RCTS, Inc.
  More Information

Responsible Party: Healthpoint Identifier: NCT01190865     History of Changes
Other Study ID Numbers: 802-247-09-021 
Study First Received: August 26, 2010
Last Updated: December 1, 2011
Health Authority: United States: Food and Drug Administration processed this record on September 30, 2016